Merck KGaA Expands German Production Facility for Allergopharma Unit - - BioPharm International

ADVERTISEMENT

Merck KGaA Expands German Production Facility for Allergopharma Unit


Merck KGaA broke ground on a new production facility for its Allergopharma unit in Reinbek near Hamburg, the company announced in a press release. The new facility is estimated to cost nearly € 40 million ($55 million) and will be constructed on the current Allergopharma premises, with completion scheduled for 2016.

The facility will manufacture products for the diagnosis and treatment of type 1 allergies such as hay fever or allergic asthma under ultrapure, sterile conditions. The expansion will be used, among other things, to serve new markets, such as China. The new building will have a surface area of more than 6,000 square meters.

The market for allergy therapies (excluding symptomatic treatments) is showing strong global growth generated by an increasing number of people with allergies and by increasing use of specific immunotherapies in many emerging markets. Global growth is estimated to be between 5% and 10% per year, according to the press release.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here